In situ hybridization on calcified tissue: Detection of RANKL mRNA in mouse osteolytic bone lesions

Acta Histochemica et Cytochemica

Volumn 38, Issue 2, 2005, Pages 143-149

  Kitazawa, Riko ^a   Kitazawa, Sohei ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone; In situ hybridization; Osteoclast; PCR; RANKL

Indexed keywords

COMPLEMENTARY DNA; DIGOXIGENIN; EDETIC ACID; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PARAFFIN; PARAFORMALDEHYDE; PHOSPHATE BUFFERED SALINE; SINGLE STRANDED DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; BONE ATROPHY; BONE LESION; BREAST CANCER; CALCIFICATION; CALVARIA; CANCER CELL; CELL PROLIFERATION; DNA PROBE; ELBOW; FEMALE; IN SITU HYBRIDIZATION; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PANNUS; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCALP; SIGNAL TRANSDUCTION; SYNOVIOCYTE;

EID: 18244397934     PISSN: 00445991     EISSN: None     Source Type: Journal    
DOI: 10.1267/ahc.38.143     Document Type: Article

References (30)

1. Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D. and Galibert, L. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390; 175-179.
2. Bromley, M. and Woolley, D. E. (1984) Histopathology of the rheumatoid lesion. Identification of cell types at sites of cartilage erosion. Arthritis Rheum. 27; 857-863.
3. Chikatsu, N., Takeuchi, Y., Tamura, Y., Fukumoto, S., Yano, K., Tsuda, E., Ogata, E. and Fujita, T. (2000) Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. Biochem. Biophys. Res. Commun. 267; 632-637.
4. Gravallese, E. M., Harada, Y., Wang, J. T., Gorn, A. H., Thornhill, T. S. and Goldring, S. R. (1998) Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 152; 943-951.
5. Guise, T. A., Yin, J. J., Taylor, S. D., Kumagai, Y., Dallas, M., Boyce, B. F., Yoneda, T. and Mundy, G. R. (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J. Clin. Invest. 98; 1544-1549.
6. Horwood, N. J., Kartsogiannis, V., Quinn, J. M., Romas, E., Martin, T. J. and Gillespie, M. T. (1999) Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun. 265; 144-150.
7. Kitazawa, R. and Kitazawa, S. (2001) Gene expression during fracture healing in normal mouse: in situ hybridization on hard tissues for investigation of regenerative mechanism. Acta Histochem. Cytochem. 34; 321-328.
8. Kitazawa, S. and Maeda, S. (1995) Development of skeletal metastases. Clin. Orthop. 312; 45-50.
9. Kitazawa, S., Kitazawa, R. and Maeda, S. (1999) In situ hybridization with polymerase chain reaction-derived single-stranded DNA probe and S1 nuclease. Histochem. Cell Biol. 111; 7-12.
10. Kitazawa, S. and Kitazawa, R. (2002) RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J. Pathol. 198; 228-236.
11. Kobayashi, K., Takahashi, N., Jimi, E., Udagawa, N., Takami, M., Kotake, S., Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Morinaga, T., Higashio, K., Martin, T. J. and Suda, T. (2000) Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/ RANKL-RANK interaction. J. Exp. Med. 191; 275-286.
12. Kohno, N., Kitazawa, S., Fukase, M., Sakoda, Y., Kanbara, Y., Furuya, Y., Ohashi, O., Ishikawa, Y. and Saitoh, Y. (1994) The expression of parathyroid hormone-related protein in human breast cancer with skeletal metastases. Surg. Today 24; 215-220.
13. Kong, Y. Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., Wong, T., Campagnuolo, G., Moran, E., Bogoch, E. R., Van, G., Nguyen, L. T., Ohashi, P. S., Lacey, D. L., Fish, E., Boyle, W. J. and Penninger, J. M. (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402; 304-309.
14. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J. and Boyle, W. J. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93; 165-176.
15. Liapis, H., Flath, A. and Kitazawa, S. (1996) Integrin ανβ3 expression by bone-residing breast cancer metastases. Diagn. Mol. Pathol. 5; 127-135.
16. Littlewood-Evans, A. J., Bilbe, G., Bowler, W. B., Farley, D., Wlodarski, B., Kokubo, T., Inaoka, T., Sloane, J., Evans, D. B. and Gallagher, J. A. (1997) The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 57; 5386-5390.
17. Mori, H., Kitazawa, R., Mizuki, S., Nose, M., Maeda, S. and Kitazawa, S. (2002) RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. Histochem. Cell Biol. 117; 283-292.
18. Nagai, M., Kyakumoto, S. and Sato, N. (2000) Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem. Biophys. Res. Commun. 269; 532-536.
19. Romas, E., Bakharevski, O., Hards, D. K., Kartsogiannis, V., Quinn, J. M., Ryan, P. F., Martin, T. J. and Gillespie, M. T. (2000) Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum. 43; 821-826.
20. Sasaki, A., Boyce, B. F., Story, B., Wright, K. R., Chapman, M., Boyce, R., Mundy, G. R. and Yoneda, T. (1995) Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55; 3551-3557.
21. Shigeyama, Y., Pap, T., Kunzler, P., Simmen, B. R., Gay, R. E. and Gaym, S. (2000) Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum. 43; 2523-2530.
22. Suda, T., Takahashi, N. and Martin, T. J. (1992) Modulation of osteoclast differentiation. Endocr. Rev. 13; 66-80.
23. Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T. and Martin, T. J. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20; 345-357.
24. Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., Takaoka, A., Yokochi, T., Oda, H., Tanaka, K., Nakamura, K. and Taniguchi, T. (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 408; 600-605.
25. Teitelbaum, S. L. (2000) Bone resorption by osteoclasts. Science 289; 1504-1508.
26. Thomas, R. J., Guise, T. A., Yin, J. J., Elliott, J., Horwood, N. J., Martin, T. J. and Gillespie, M. T. (1999) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140; 4451-4458.
27. Trentham, D. E., Townes, A. S. and Kang, A. H. (1977) Autoimmunity to type II collagen an experimental model of arthritis. J. Exp. Med. 146; 857-868.
28. Wong, B. R., Josien, R., Lee, S. Y., Vologodskaia, M., Steinman, R. M. and Choi, Y. (1998) The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor. J. Biol. Chem. 273; 28355-28359.
29. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N. and Suda, T. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95; 3597-3602.
30. Yoneda, T., Sasaki, A., Dunstan, C., Williams, P. J., Bauss, F., DeClerck, Y. A. and Mundy, G. R. (1997) Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J. Clin. Invest. 99; 2509-2517.